NCT00151996: Safety and Tolerability of SPD503 and Psychostimulants in Children and Adolescents Aged 6-17 With Attention-Deficit/Hyperactivity Disorder (ADHD) |
|
|
| Completed | 2 | 75 | NA | Methylphenidate + SPD503 (Guanfacine hydrochloride), Amphetamine + SPD503 | Shire | Attention Deficit Disorder With Hyperactivity | 12/04 | 12/04 | | |
NCT00150592: Safety, Tolerability and Efficacy of SPD503 in Treating ADHD in Children Aged 6-17 |
|
|
| Completed | 2 | 182 | NA | SPD503 (Guanfacine HCl), Placebo | Shire | Attention Deficit Disorder With Hyperactivity | 10/05 | 10/05 | | |
NCT01470469: SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP) |
|
|
| Completed | 2 | 83 | US | SPD503 (extended-release Guanfacine hydrochloride), Intuniv, Placebo | Shire | Generalized Anxiety Disorder (GAD), Anxiety, Separation, Phobia, Social | 07/13 | 07/13 | | |
